Chu Jing.Clinicopathological characteristics and research advances of pediatric Wilms tumor[J].Journal of Clinical Pediatric Surgery,2025,(03):296-300.[doi:10.3760/cma.j.cn101785-202206038-018]
儿童肾母细胞瘤的临床病理及分子遗传学研究进展
- Title:
- Clinicopathological characteristics and research advances of pediatric Wilms tumor
- Keywords:
- Wilms Tumor; Clinical Characteristics and Pathology; Molecular Genetics; Surgical Procedures; Operative; Child
- 摘要:
- 肾母细胞瘤(wilms tumor,WT)是来源于肾胚基细胞的恶性胚胎性肿瘤,具有早期诊断困难、治疗后易复发、部分病理亚型预后差等特点。临床、病理组织学检查和分子遗传学检测在WT的正确诊断、指导治疗和预后评估方面扮演着重要角色。本文就WT临床病理学特征、分子遗传学、诊断、鉴别诊断的研究进展进行综述。
- Abstract:
- Wilms tumor (WT) is a malignant embryonal tumor derived from renal blastoid cells.It is characterized by a difficult early diagnosis,frequent recurrence after treatment and a poor prognosis of some pathological subtypes.A combination of clinical profiling,pathological examination and molecular genetic test is indispensable for making an accurate diagnosis,guiding therapy and prognostic prediction.This review summarized the clinicopathologic features,molecular genetics,diagnosis and differential diagnosis of WT as well as its research advances.
参考文献/References:
[1] 中华医学会小儿外科学分会泌尿外科学组.儿童肾母细胞瘤诊疗专家共识[J].中华小儿外科杂志,2020,41(7):585-590.DOI:10.3760/cma.j.cn421158-20190805-00479. Group of Urology,Branch of Pediatric Surgery,Chinese Medical Association.Expert Consensus on Managing Pediatric Nephroblastoma[J].Chin J Pediatr Surg,2020,41(7):585-590.DOI:10.3760/cma.j.cn421158-20190805-00479.
[2] Bahoush G,Saeedi E.Outcome of children with Wilms’tumor in developing countries[J].J Med Life,2020,13(4):484-489.DOI:10.25122/jml-2019-0084.
[3] Cunningham ME,Klug TD,Nuchtern JG,et al.Global disparities in Wilms tumor[J].J Surg Res,2020,247:34-51.DOI:10.1016/j.jss.2019.10.044.
[4] WHO Classification of Tumours Editorial Board.WHO classification of tumours:urinary and male genital tumors[M].5th ed.Lyon:IARC Press,2022.
[5] 徐丰,郭春娜,李博.CT诊断肾母细胞瘤患儿的价值观察[J].中国CT和MRI杂志,2021,19(1):135-137.DOI:10.3969/j.issn.1672-5131.2021.01.046. Xu F,Guo CN,Li B.Diagnostic value of CT for nephroblastoma children[J].Chin J CT and MRI,2021,19(1):135-137.DOI:10.3969/j.issn.1672-5131.2021.01.046.
[6] 陈慧敏,殷一铭,赵晓宁.小儿肾母细胞瘤的超声图像特点分析[J].黑龙江医学,2019,43(7):783-784.DOI:10.3969/j.issn.1004-5775.2019.07.034. Chen HM,Yin YM,Zhao XN.Ultrasonographic characteristics of nephroblastoma in children[J].Heilongjiang Med J,2019,43(7):783-784.DOI:10.3969/j.issn.1004-5775.2019.07.034.
[7] 杨文萍,武海燕,张文,等.儿童肾母细胞瘤病理诊断共识[J].中华病理学杂志,2017,46(3):149-154.DOI:10.3760/cma.j.issn.0529-5807.2017.03.002. Yang WP,Wu HY,Zhang W,et al.Consensus on pathologic diagnosis of Wilms’tumor in children[J].Chin J Pathol,2017,46(3):149-154.DOI:10.3760/cma.j.issn.0529-5807.2017.03.002.
[8] 何巧,张道恩,陈湾湾,等. "肾母细胞瘤的治疗建议CCCG-WT-2016方案" 2019修订版病理分类应用效果分析[J].中华病理学杂志,2020,49(4):324-328.DOI:10.3760/cma.j.cn112151-20191101-00706. He Q,Zhang DE,Chen WW,et al.Application of pathological classification of "CCCG-WT-2016" (2019 Revision) for treating Wilms tumors[J].Chin J Pathol,2020,49(4):324-328.DOI:10.3760/cma.j.cn112151-20191101-00706.
[9] Morgan ED,Yahaya JJ,Ngaiza AI,et al.Immunohistochemical expression of P53 protein in nephroblastoma:a predictor of unfavorable prognosis[J].J Egypt Natl Canc Inst,2023,35(1):23.DOI:10.1186/s43046-023-00183-2.
[10] Zhang LJ,Jiao H,Shen MM,et al.Clinical significance of tumoral PD-L1 expression in Wilms tumors[J].J Pediatr Urol,2022,18(1):14.e1-14.e8.DOI:10.1016/j.jpurol.2021.10.015.
[11] Atwa AM,Hafez AT,Abdelhameed M,et al.Does immunohistochemical staining of P53,Ki 67 and cyclin A accurately predict Wilms tumor recurrence and survival?[J].Arab J Urol,2022,20(3):107-114.DOI:10.1080/2090598X.2022.2058240.
[12] Zapata-Tarres M,Juarez-Villegas LE,Maldonado-Valenzuela A,et al.Expression of YY1 in Wilms tumors with favorable histology is a risk factor for adverse outcomes[J].Future Oncol,2019,15(11):1231-1241.DOI:10.2217/fon-2018-0764.
[13] Grundy PE,Breslow NE,Li S,et al.Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor:a report from the National Wilms Tumor Study Group[J].J Clin Oncol,2005,23(29):7312-7321.DOI:10.1200/JCO.2005.01.2799.
[14] Dix DB,Fernandez CV,Chi YY,et al.Augmentation of therapy for combined loss of heterozygosity 1p and 16q in favorable histology Wilms tumor:a Children’s Oncology Group AREN0532 and AREN0533 study report[J].J Clin Oncol,2019,37(30):2769-2777.DOI:10.1200/JCO.18.01972.
[15] Gratias EJ,Jennings LJ,Anderson JR,et al.Gain of 1q is associated with inferior event-free and overall survival in patients with favorable histology Wilms tumor:a report from the Children’s Oncology Group[J].Cancer,2013,119(21):3887-3894.DOI:10.1002/cncr.28239.
[16] Gratias EJ,Dome JS,Jennings LJ,et al.Association of chromosome 1q gain with inferior survival in favorable-histology Wilms tumor:a report from the Children’s Oncology Group[J].J Clin Oncol,2016,34(26):3189-3194.DOI:10.1200/JCO.2015.66.1140.
[17] Gadd S,Huff V,Skol AD,et al.Genetic changes associated with relapse in favorable histology Wilms tumor:a Children’s Oncology Group AREN03B2 study[J].Cell Rep Med,2022,3(6):100644.DOI:10.1016/j.xcrm.2022.100644.
[18] Scott RH,Murray A,Baskcomb L,et al.Stratification of Wilms tumor by genetic and epigenetic analysis[J].Oncotarget,2012,3(3):327-335.DOI:10.18632/oncotarget.468.
[19] Perlman EJ,Grundy PE,Anderson JR,et al.WT1 mutation and 11P15 loss of heterozygosity predict relapse in very low-risk Wilms tumors treated with surgery alone:a Children’s Oncology Group study[J].J Clin Oncol,2011,29(6):698-703.DOI:10.1200/JCO.2010.31.5192.
[20] Treger TD,Chagtai T,Butcher R,et al.Somatic TP53 mutations are detectable in circulating tumor DNA from children with anaplastic Wilms tumors[J].Transl Oncol,2018,11(6):1301-1306.DOI:10.1016/j.tranon.2018.08.006.
[21] Gao Z,Lin J,Hong P,et al.Identification of key genes in Wilms tumor based on high-throughput RNA sequencing and their impacts on prognosis and immune responses[J].J South Med Univ,2024,44(4):727-738.DOI:10.12122/j.issn.1673-4254.2024.04.15.
[22] Liu P,Zhuo ZJ,Li WY,et al.TP53 rs1042522 C>G polymorphism and Wilms tumor susceptibility in Chinese children:a four-center case-control study[J].Biosci Rep,2019,39(1):BSR20181891.DOI:10.1042/BSR20181891.
[23] Fu W,Zhuo ZJ,Jia W,et al.Association between TP53 gene Arg-72Pro polymorphism and Wilms’tumor risk in a Chinese population[J].Onco Targets Ther,2017,10:1149-1154.DOI:10.2147/OTT.S131014.
[24] Chiang MR,Kuo CW,Wang WC,et al.Correlations between histological and array comparative genomic hybridization characterizations of Wilms tumor[J].Pathol Oncol Res,2019,25(3):1199-1206.DOI:10.1007/s12253-019-00601-8.
[25] Pignata L,Palumbo O,Cerrato F,et al.Both epimutations and chromosome aberrations affect multiple imprinted loci in aggressive Wilms tumors[J].Cancers (Basel),2020,12(11):3411.DOI:10.3390/cancers12113411.
[26] Jablonowski CM,Gil HJ,Pinto EM,et al.TERT expression in Wilms tumor is regulated by promoter mutation or hypermethylation,WT1,and N-MYC[J].Cancers (Basel),2022,14(7):1655.DOI:10.3390/cancers14071655.
[27] Wegert J,Ishaque N,Vardapour R,et al.Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type Wilms tumors[J].Cancer Cell,2015,27(2):298-311.DOI:10.1016/j.ccell.2015.01.002.
[28] Walz AL,Ooms A,Gadd S,et al.Recurrent DGCR8,DROSHA,and SIX homeodomain mutations in favorable histology Wilms tumors[J].Cancer Cell,2015,27(2):286-297.DOI:10.1016/j.ccell.2015.01.003.
[29] Spreafico F,Ciceri S,Gamba B,et al.Chromosomal anomalies at 1q,3,16q,and mutations of SIX1 and DROSHA genes underlie Wilms tumor recurrences[J].Oncotarget,2016,7(8):8908-8915.DOI:10.18632/oncotarget.6950.
[30] Ciceri S,Montalv?o-de-Azevedo R,Tajbakhsh A,et al.Analysis of the mutational status of SIX1/2 and microRNA processing genes in paired primary and relapsed Wilms tumors and association with relapse[J].Cancer Gene Ther,2021,28(9):1016-1024.DOI:10.1038/s41417-020-00268-3.
[31] Zhao ML,Yin MZ,Kuick CH,et al.Congenital mesoblastic neph-roma is characterised by kinase mutations including EGFR internal tandem duplications,the ETV6-NTRK3 fusion,and the rare KLHL7-BRAF fusion[J].Histopathology,2020,77(4):611-621.DOI:10.1111/his.14194.
[32] Chen SH,Li M,Li R,et al.Clear cell sarcoma of the kidney in children:a clinopathologic analysis of three cases[J].Int J Clin Exp Pathol,2020,13(4):771-777.DOI:10.1002/pbc.28151.
[33] Yao XF,Zhang M,Tao J,et al.Clear cell sarcoma of kidney in children:a clinicopathological and molecular genetics analysis[J].Chin J Pathol,2024,53(7):731-733.DOI:10.3760/cma.j.cn112151-20231020-00279.
[34] Gokden N,Dawson K,Lindberg M.Malignant rhabdoid tumor arising in a mixed epithelial,stromal tumor of kidney:report of a male case,review of the literature[J].Pathol Res Pract,2020,216(10):153151.DOI:10.1016/j.prp.2020.153151.
[35] 王金湖,蔡嘉斌,李民驹,等.儿童肾母细胞瘤国际及国内诊治方案解读[J].临床小儿外科杂志,2020,19(9):765-774.DOI:10.3969/j.issn.1671-6353.2020.09.002. Wang JH,Cai JB,Li MJ,et al.Recent international and domestic advances in the diagnosis and treatment of Wilms tumor[J].DOI:10.3969/j.issn.1671-6353.2020.09.002.
[36] Hall G,Grant R,Weitzman S,et al.Predictors of surgical outcome in Wilms’tumor:a single-institution comparative experience[J].J Pediatr Surg,2006,41(5):966-971.DOI:10.1016/j.jpedsurg.2006.01.017.
[37] Mitchell C,Pritchard-Jones K,Shannon R,et al.Immediate nephrectomy versus preoperative chemotherapy in the management of non-metastatic Wilms’tumour:results of a randomised trial (UKW3) by the UK Children’s Cancer Study Group[J].Eur J Cancer,2006,42(15):2554-2562.DOI:10.1016/j.ejca.2006.05.026.
[38] 谢晨捷,顾松,田瑞成,等.儿童复发肾母细胞瘤的治疗及预后相关因素分析[J].临床小儿外科杂志,2021,20(5):430-436.DOI:10.12260/Icxewkzz.2021.05.007. Xie CJ,Gu S,Tian RC,et al.Treatments and prognostic factors of recurrent Wilm’s tumor in children[J].J Clin Ped Sur,2021,20(5):430-436.DOI:10.12260/Icxewkzz.2021.05.007.
相似文献/References:
[1]何军,肖海波,王淑华,等. p53免疫组化判定肾母细胞瘤预后的研究[J].临床小儿外科杂志,2016,15(02):163.
[2]何炜婧,柳龚堡,董岿然..肾母细胞瘤伴静脉瘤栓的治疗探讨[J].临床小儿外科杂志,2017,16(05):426.
[3]王金湖,蔡嘉斌,李民驹,等.儿童肾母细胞瘤国际及国内诊治方案解读[J].临床小儿外科杂志,2020,19(09):765.[doi:10.3969/j.issn.1671-6353.2020.09.002]
Wang Jinhu,Cai Jiabin,Li Minju,et al.Recent international and domestic advances in the diagnosis and treatment of Wilms tumor[J].Journal of Clinical Pediatric Surgery,2020,19(03):765.[doi:10.3969/j.issn.1671-6353.2020.09.002]
[4]谢晨捷,顾松,田瑞成,等.儿童复发肾母细胞瘤的治疗及预后相关因素分析[J].临床小儿外科杂志,2021,20(05):430.[doi:10.12260/lcxewkzz.2021.05.007]
Xie Chenjie,Gu Song,Tian Ruicheng,et al.Treatment and prognostic factors of recurrent wilm’s tumor in children[J].Journal of Clinical Pediatric Surgery,2021,20(03):430.[doi:10.12260/lcxewkzz.2021.05.007]
[5]周恩卿,董瑞.黄连素在儿童胚胎源性肿瘤中的研究进展[J].临床小儿外科杂志,2023,22(12):1135.[doi:10.3760/cma.j.cn101785-202208042-008]
Zhou Enqing,Dong Rui.Research advances of berberine in pediatric embryonal tumors[J].Journal of Clinical Pediatric Surgery,2023,22(03):1135.[doi:10.3760/cma.j.cn101785-202208042-008]
[6]常晓峰,王焕民,王佳荣,等.细胞减灭术联合腹腔热灌注化疗在局部反复复发肾母细胞瘤治疗中的应用[J].临床小儿外科杂志,2024,(05):464.[doi:10.3760/cma.j.cn101785-202203047-012]
Chang Xiaofeng,Wang Huanmin,Wang Jiarong,et al.Application of cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for locally recurrent Wilms tumor[J].Journal of Clinical Pediatric Surgery,2024,(03):464.[doi:10.3760/cma.j.cn101785-202203047-012]
[7]覃善璐,董岿然.肾母细胞瘤胚胎学起源的研究进展[J].临床小儿外科杂志,2024,(07):697.[doi:10.3760/cma.j.cn101785-202207041-018]
Qin Shanlu,Dong Kuiran.Research advances in embryological origin of Wilms tumor[J].Journal of Clinical Pediatric Surgery,2024,(03):697.[doi:10.3760/cma.j.cn101785-202207041-018]
[8]王雅琦,李万富,阿依古再丽·麦麦江,等.miR-20a-5p对人肾母细胞瘤增殖、迁移、侵袭及凋亡的影响[J].临床小儿外科杂志,2024,(11):1054.[doi:10.3760/cma.j.cn101785-202305039-010]
Wang Yaqi,Li Wanfu,Ayiguzaili Maimaijiang,et al.Study on the effect of miR-20a-5p on proliferation,migration,invasion,and apoptosis in human nephroblastoma[J].Journal of Clinical Pediatric Surgery,2024,(03):1054.[doi:10.3760/cma.j.cn101785-202305039-010]
备注/Memo
收稿日期:2022-6-16。
基金项目:安徽医科大学校科研基金(2023xkj218)
通讯作者:储婧,Email:chujing198603@163.com